ArticleLeukemia2016

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis.

M Jawhar et al.PubMed ↗Publisher ↗

No numbers read from the abstract.